<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>


<div class="uk-container">
<p>Adjunct corticosteroid therapy is indicated in the treatment of
    tuberculous meningitis as its use along with appropriate antituberculosis drugs is associated with a lower
    mortality. For pa- tients with tuberculous meningitis, dexamethasone or prednisolone is recommended for a total of 6
    to 8 weeks. An initial dose of 8 mg per day of dexamethasone for children < 25 kg and 12 mg per day for children >
    25 kg and adults can be used. The initial dose is given for 3 weeks and then the dose should be tapered during the
    following 3 weeks. Adjunctive corticosteroids in treatment of pericardial tuberculosis did not reduce mortality,
    tamponade or constrictive physiology in a large randomized clinical trial and are thus no longer routinely
    recommended. Some experts would use corticosteroids in selected patients with TB peri- carditis: those with large
    effusions and/or high levels of inflam- mation in pericardial fluid.</p>

<h1>Table 19. Guidelines for Treatment of Extrapulmonary* Tuberculosis: Length of therapy and Adjunctive Use of
    Corticosteroids</h1>

    <table class="uk-table uk-table-small uk-table-divider">
    <tr>
        <th>Site</th>
        <th>Length of therapy with standard regimen and normal host (months)</th>
        <th>Corticosteroids</th>
        <th>Steroid dosing A (adults) C (children)</th>
        <th>Additional management considerations</th>
    </tr>
    <tr>
        <td>Lymph node</td>
        <td>6</td>
        <td>Not recommended</td>
        <td></td>
        <td>Pursue microbiologic proof of diagnosis prior to starting Rx</td>
    </tr>
    <tr>
        <td>Bone (non-vertebral) and joint</td>
        <td>6 to 9</td>
        <td>Not recommended</td>
        <td></td>
        <td>Extend to 12 months if hardware is present</td>
    </tr>
    <tr>
        <td>Spine without meningitis</td>
        <td>6 to 9</td>
        <td>Not recommended for TB rx but may be indicated for cord compression</td>
        <td></td>
        <td rowspan="2">Most spine infection can be cured with medical Rx. Surgery indicated for relief of cord
            compression, progressive disease despite medical therapy, instability of the spine.
        </td>
    </tr>
    <tr>
        <td>Spine with meningitis</td>
        <td>9 to 12</td>
        <td>Strongly recommended</td>
        <td rowspan="2">A and C >= 25kg: 12 mg/day of dexamethasone x 3 weeks followed by 3- week taper <p>C < 25kg:8 mg
            /day of dexamethasone for 3 weeks followed by 3- week taper</p></td>
    </tr>
    <tr>
        <td>CNS tuberculosis including meningitis</td>
        <td>6 to 9</td>
        <td>Strongly recommended</td>
        <td>Negative CSF culture or PCR test does NOT exclude this diagnosis <p>Follow CSF profile for response to
            therapy</p></td>
    </tr>
    <tr>
        <td>Pleural disease</td>
        <td>6</td>
        <td>Not recommended</td>
        <td></td>
        <td>Empyema may require decortication</td>
    </tr>
    <tr>
        <td>Pericarditis</td>
        <td>6</td>
        <td>NO LONGER routinely RECOMMENDED</td>
        <td></td>
        <td>Consider steroids for patients at highest risk of later constriction:
            large pericardial effusions high levels of inflammatory cells or markers in pericardial fluid those with
            early signs of constriction
        </td>
    </tr>
    <tr>
        <td>Disseminated disease</td>
        <td>6</td>
        <td>Not recommended</td>
        <td></td>
        <td>Obtain cultures from blood, urine and sputum in addition to clinically apparent sites of disease.</td>
    </tr>
    <tr>
        <td>Genitourinary</td>
        <td>6</td>
        <td>Not recommended</td>
        <td></td>
        <td></td>
    </tr>
    <tr>
        <td>Peritoneal</td>
        <td>6</td>
        <td>Not recommended</td>
        <td></td>
        <td></td>
    </tr>
</table>

<p>*ALWAYS EVALUATE for concomitant pulmonary involvement with respiratory samples for smear and culture (regardless of
    chest imaging findings).</p>

<p>Based on CID 2016:63 (1 October) â€¢ Nahid et al</p>
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
</html>
